Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m).
Subscribe to our email newsletter
The company has purchased single share at an amount of NIS1.405 ($0.36).
The acquired shares represent all the shares of Teva in Proteologics and also represent nearly 31.35% of Proteologics issued and outstanding share capital.
Proteologics is a public traded company listed on the Tel Aviv Stock Exchange.
XTL focuses on late stage clinical development of drugs to treat multiple myeloma, schizophrenia and hepatitis C.